C

Celcuity
D

CELC

112.620
USD
-0.37
(-0.33%)
Market Closed
Volume
13,896
EPS
-4
Div Yield
-
P/E
-30
Market Cap
5,211,069,189
Overview
Related Instruments
C
CARG
33.330 USD
-0.225
(-0.67%)
C
CCO
2.37500 USD
0.00000
(0.00%)
C
CE
64.110 USD
0.570
(0.90%)
CELH
CELH
34.080 USD
-0.250
(-0.73%)
C
CENX
62.600 USD
-0.915
(-1.44%)
CMCSA
CMCSA
27.930 USD
-0.100
(-0.36%)
CME
CME
305.04 USD
8.15
(2.75%)
CNC
CNC
35.110 USD
1.185
(3.49%)
More

Title: Celcuity

Sector: Healthcare
Industry: Biotechnology
Celcuity Inc is a clinical-stage biotechnology company developing targeted therapies for multiple solid tumors. Its candidate, gedatolisib, is a kinase inhibitor of the PI3K/AKT/mTOR (PAM) pathway, binding all class I PI3K isoforms and mTORC1/2, offering comprehensive inhibition with a mechanism and pharmacokinetics differentiated from other therapies. The Phase 3 VIKTORIA-1 trial, evaluating gedatolisib with fulvestrant, with or without palbociclib, in HR+/HER2- breast cancer, has completed enrollment and reported results for PIK3CA WT tumors, with cohort 2 (PIK3CA MT) also enrolled. Phase 3 VIKTORIA-2 and Phase 1b/2 CELC-G-201 trials, evaluating combinations in endocrine-resistant HR+/HER2- breast cancer andmetastatic castration-resistant prostate cancer, are ongoing.
Smarter Decisions,Together
FacebookTwitterYoutubeLinkedIn
App Store
iOS
Google Play
Android
Social Network
The NetworkSignals NetworkIdeas NetworkBest TradersUser Reviews for Brokers
Company
Contact usAbout usTerms Of UsePrivacy PolicyCookies PolicyDisclaimerHouse rulesHelp Centeradvertising with ArincenOur servicesReferral programDownload Mobile App
Products
Risk CalculatorPip CalculatorAdvance Chart
Markets
Exchange RatesCommodities RatesCryptocurrencies RatesIndices RatesUS Stocks Rates

Risk Disclosure: Trading in financial instruments involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks. Never invest money you cannot afford to lose, and carefully assess the suitability of complex products such as CFDs and derivatives in light of your financial situation. Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed. Arincen would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes.

Arincen and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website. It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Arincen and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website. Arincen may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.

© 2026 - Arincen L.L.C-FZ - License No. 2420098.01. All Rights Reserved.